Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. BA
6. SPY
7. META
8. HOOD
9. INTC
10. JBLU

Go back to Celator Pharmaceuticals (CPXX) Misses Q4 EPS by 1c

Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results

March 21, 2016 8:20 AM EDT

EWING, N.J., March 21, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2015.

"In 2015, Celator continued to meet important milestones with VYXEOS and the CombiPlex® platform," said Scott Jackson, chief executive officer of Celator. "Recently, we announced positive results from our Phase 3 trial in patients with high-risk (secondary) acute myeloid leukemia (AML), comparing VYXEOS to the long... More